Karachi: Citi Pharma Limited has announced the receipt of authorization from the Competition Commission of Pakistan (CCP) for its proposed acquisition of a 100% shareholding in Pakheim International Pharma (Private) Limited. According to the company's report dated October 19, 2026, the CCP's order, dated October 9, 2026, grants permission under Section 31(1)(d)(i) of the Competition Act, 2010, following a review that determined the transaction poses no competition concerns.

The acquisition will proceed as outlined in the Share Purchase Agreement from May 6, 2026, subject to completion of necessary legal, regulatory, and other formalities. Citi Pharma Limited has committed to providing further updates upon reaching significant milestones in the transaction process.

According to information available from the Pakistan Stock Exchange (PSX), Citi Pharma Limited's progress with this acquisition is closely monitored by its stakeholders. The transaction is seen as a strategic move within the pharmaceutical sector, aiming to enhance the company's market position and operational capabilities.

The development marks a significant step for Citi Pharma Limited, reflecting its continued expansion efforts and strategic growth within the designated market category of pharmaceuticals. Further disclosures by the company are anticipated as the transaction advances through its subsequent phases.